Placeholder Banner

HHS Drug Importation Plan a "Misguided Attempt to Keep an Ill-Informed Campaign Promise"

July 31, 2019
Media Contact
Brian Newell
202.312.9268

Following the introduction of the Trump administration’s drug importation proposal, BIO’s President and CEO Jim Greenwood issued the following statement:

“There is simply no way to adopt an importation scheme that doesn’t jeopardize the health and well-being of America’s patients. That’s been the judgment of past FDA commissioners who served under both Republican and Democratic administrations. Not only will this undermine the safety of our nation’s drug supply, but nonpartisan budget experts have said that the costs of implementing drug importation will largely outweigh any savings the Administration may hope to achieve. This is a misguided attempt to keep a ill-informed campaign promise. The burden is on the leadership of the Department of Health and Human Services to ensure this actually leads to lower costs for consumers—not just for insurance companies and pharmacy benefit managers—and no harm is inflicted on patients and local communities.”

Discover More
Today, the Centers for Medicare and Medicaid Services announced that it is proposing to create a new Medicare-severity-diagnosis related group (MS-DRG) designed specifically for reimbursing providers administering CAR T-cell therapies to cancer…
BIO’s Tom DiLenge, President of Advocacy, Law & Public Policy Division issued the following statement today after the Trump administration adopted a “Notice of Benefit and Payment Parameters for 2021” that allows health plans to block drug…
In a new video, Cynthia Bens, patient advocate and Senior Vice President of Public Policy at the Personalized Medicine Coalition, shares her views on how adopting foreign price controls for prescription medicines will impact patients in the U.S. …